Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.47 |
| ▸ | LARS1 | Q9P2J5 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1797504 | 0.88 | LARS1 (0.49) | MEN1KMT2ALARS1 | |
| SCHEMBL18630612 | 0.88 | LARS1 (0.49) | MEN1KMT2ALARS1 | |
| SCHEMBL1799778 | 0.78 | LARS1 (0.58) | LARS1 | |
| SCHEMBL7102573 | 0.75 | DPP4 (0.69) | MEN1KMT2AADORA3 | |
| SCHEMBL1797391 | 0.73 | SLC29A1 (0.56) | ADORA3 | |
| SCHEMBL1800307 | 0.73 | CA1 (0.55) | MEN1KMT2AADORA3 | |
| SCHEMBL12617951 | 0.73 | CA1 (0.55) | MEN1KMT2AADORA3 | |
| SCHEMBL5341890 | 0.73 | CA1 (0.55) | MEN1KMT2AADORA3 | |
| SCHEMBL1795761 | 0.72 | SLC29A1 (0.76) | — | |
| SCHEMBL658713 | 0.71 | MEN1 (0.66) | MEN1KMT2AADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210070798-A1 | Inhibitors of E1 activating enzymes | ECE1, RNASE1, RCE1 | MEN1 2363/4885KMT2A 2611/4885ADORA3 3584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.